ParcelBio is a next-generation mRNA therapeutics company developing the most potent and durable mRNA medicines. The company’s lead program is a potentially first-in-class, multi-targeted in vivo CAR-T cell therapy designed to treat dozens of autoimmune disorders, with plans to enter the clinic in 2027. Founded by experts in RNA medicines and backed by prominent investors, ParcelBio is pushing the frontier of what’s possible with mRNA medicines.